{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:24:59Z","timestamp":1793057099355,"version":"4.5.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.resinv.2024.04.008","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T19:58:41Z","timestamp":1714507121000},"page":"589-596","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The effect of nintedanib on health-related quality of life in Japanese patients with progressive fibrosing interstitial lung diseases: A subset analysis of the INBUILD trial"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3994-874X","authenticated-orcid":false,"given":"Yoshikazu","family":"Inoue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideya","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Nishioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6456-2825","authenticated-orcid":false,"given":"Tomohiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus B.","family":"Rohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Suda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2024.04.008_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0076-2018","article-title":"Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases","volume":"27","author":"Cottin","year":"2018","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.resinv.2024.04.008_bib2","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","article-title":"Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities","volume":"8","author":"George","year":"2020","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.resinv.2024.04.008_bib3","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2024.04.008_bib4","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0075-2018","article-title":"Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases","volume":"27","author":"Swigris","year":"2018","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.resinv.2024.04.008_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00681-2021","article-title":"Developing a conceptual model of symptoms and impacts in progressive fibrosing interstitial lung disease to evaluate patient-reported outcome measures","volume":"8","author":"Wijsenbeek","year":"2022","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.resinv.2024.04.008_bib6","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00161-2019","article-title":"Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases","volume":"54","author":"Wollin","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2024.04.008_bib8","series-title":"European Commission approves third nintedanib indication in pulmonary fibrosis","year":"2020"},{"key":"10.1016\/j.resinv.2024.04.008_bib11","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.04.008_bib12","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.04538-2020","article-title":"Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial","volume":"59","author":"Flaherty","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2024.04.008_bib13","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00752-2023","article-title":"Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis","volume":"63","author":"Wijsenbeek","year":"2024","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2024.04.008_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2021.106574","article-title":"Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial","volume":"187","author":"Inoue","year":"2021","journal-title":"Respir Med"},{"key":"10.1016\/j.resinv.2024.04.008_bib15","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.resinv.2022.06.009","article-title":"Effects of nintedanib on disease progression and safety in Japanese patients with progressive fibrosing interstitial lung diseases: further subset analysis from the whole INBUILD trial","volume":"60","author":"Ogura","year":"2022","journal-title":"Respir Investig"},{"key":"10.1016\/j.resinv.2024.04.008_bib16","article-title":"Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease","volume":"4","author":"Flaherty","year":"2017","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.resinv.2024.04.008_bib17","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00145-2020","article-title":"The Living with Pulmonary Fibrosis questionnaire in progressive fibrosing interstitial lung disease","volume":"7","author":"Swigris","year":"2021","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.resinv.2024.04.008_bib18","article-title":"Responsiveness and meaningful change thresholds of the Living with Pulmonary Fibrosis (L-PF) questionnaire Dyspnoea and Cough scores in patients with progressive fibrosing interstitial lung diseases","volume":"9","author":"Swigris","year":"2022","journal-title":"BMJ Open Respir Res"},{"key":"10.1016\/j.resinv.2024.04.008_bib19","series-title":"Quality of life and pharmacoeconomics in clinical trials","first-page":"575","article-title":"Language and translation issues","author":"Acquadro","year":"1996"},{"key":"10.1016\/j.resinv.2024.04.008_bib20","series-title":"Linguistic validation manual for health outcome assessments","author":"Acquadro","year":"2021"},{"key":"10.1016\/j.resinv.2024.04.008_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12931-017-0621-y","article-title":"Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry","volume":"18","author":"Kreuter","year":"2017","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2024.04.008_bib22","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.chest.2019.11.042","article-title":"Disease severity and quality of life in patients with idiopathic pulmonary fibrosis: a cross-sectional analysis of the IPF-PRO Registry","volume":"157","author":"O'Brien","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2024.04.008_bib23","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s12931-021-01790-0","article-title":"Validation and minimum important difference of the UCSD Shortness of Breath Questionnaire in fibrotic interstitial lung disease","volume":"22","author":"Chen","year":"2021","journal-title":"Respir Res"},{"key":"10.1016\/j.resinv.2024.04.008_bib24","doi-asserted-by":"crossref","first-page":"SI43","DOI":"10.1093\/rheumatology\/keac325","article-title":"Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease","volume":"62","author":"Kreuter","year":"2023","journal-title":"Rheumatology"},{"key":"10.1016\/j.resinv.2024.04.008_bib25","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2024.04.008_bib26","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1111\/imj.14837","article-title":"Understanding cough in interstitial lung disease: a cross-sectional study on the adequacy of treatment","volume":"51","author":"Lan","year":"2021","journal-title":"Intern Med J"},{"key":"10.1016\/j.resinv.2024.04.008_bib27","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00039-2023","article-title":"Understanding patient experience of chronic cough in interstitial lung disease","volume":"9","author":"Mann","year":"2023","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.resinv.2024.04.008_bib28","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1111\/resp.12989","article-title":"Health-related quality of life in idiopathic pulmonary fibrosis: data from the Australian IPF Registry","volume":"22","author":"Glaspole","year":"2017","journal-title":"Respirology"},{"key":"10.1016\/j.resinv.2024.04.008_bib29","series-title":"Associations between L-PF questionnaire dyspnea scores and outcomes in patients with progressive fibrosing ILDS: data from the INBUILD trial [abstract A102]","author":"Wijsenbeek","year":"2023"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534524000613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534524000613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,2]],"date-time":"2024-11-02T08:02:46Z","timestamp":1730534566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534524000613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2212534524000613"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2024.04.008","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of nintedanib on health-related quality of life in Japanese patients with progressive fibrosing interstitial lung diseases: A subset analysis of the INBUILD trial","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2024.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V. on behalf of The Japanese Respiratory Society.","name":"copyright","label":"Copyright"}]}}